Biotechnology

TC BIOPHARM (HOLDINGS) PLC SPON ADS EACH REP 4000 SHS (POST SPLIT)

TC BIOPHARM (HOLDINGS) PLC released FY2024 9 Months Earnings on May 9, 2025 (EST) with actual revenue of USD 0 and EPS of USD -127.7742

TC Biopharm (Holdings) PLC released FY2024 annual earnings on May 9, 2025 (EST) with actual revenue of USD 0 and EPS of USD -164.778

TC BIOPHARM (HOLDINGS) PLC released FY2024 Q4 earnings on May 9, 2025 (EST), with actual revenue of USD 0 and EPS of USD -25.3148

TC BIOPHARM (HOLDINGS) PLC released FY2024 Q3 earnings on May 9, 2025 (EST), with actual revenue of USD 0 and EPS of USD -26.9906

TCBPY.US released FY2024 Q2 earnings on November 25 (BJT), with actual revenue of 0 USD and EPS of -100.7835 USD

TC Biopharm (Holdings) PLC released FY2023 9 Months Earnings on November 25, 2024 (EST) with actual revenue of USD 0 and EPS of USD 0

TC BIOPHARM (HOLDINGS) PLC released FY2023 Q3 earnings on November 25, 2024 (EST), with actual revenue of USD 0 (forecast USD 618.39K) and actual EPS of USD 0

TC BIOPHARM (HOLDINGS) PLC released FY2023 Q2 earnings on November 25 (EST), actual revenue 0 USD (forecast 618.39 K USD), actual EPS 0 USD

TCBPY.US released FY2023 Semi-Annual Earnings on November 25 (BJT) with actual revenue of 0 USD and EPS of 0 USD

TCBPY.US released FY2024 Semi-Annual Earnings on November 25 (BJT), with actual revenue of 0 USD and EPS of -413.194 USD

TCBPY.US released FY2024 Q1 earnings on May 15 (BJT) with actual revenue of 0 USD and EPS of 0 USD

TCBPY.US released FY2023 Q1 earnings on May 15 (BJT), actual revenue 0 USD (forecast 618.39 K USD), actual EPS 0 USD

TC BIOPHARM (HOLDINGS) PLC released FY2023 Q4 earnings on April 1, 2024 (EST), actual revenue USD 0 (forecast USD 618.39K), actual EPS USD 0

TCBPY.US released FY2022 annual earnings on April 1 (BJT), actual revenue 4.666 M USD (forecast 2.472 M USD), actual EPS 0 USD

TCBPY.US released FY2022 Q4 earnings on April 1 (BJT), actual revenue 1.723 M USD (forecast 618.39 K USD), actual EPS 0 USD

TCBPY.US released FY2023 annual earnings on April 1 (BJT), actual revenue 0 USD (forecast 2.471 M USD), actual EPS 0 USD

TCBPY.US released FY2022 Q3 earnings on April 1 (BJT), actual revenue 1.58 M USD (forecast 611.93 K USD), actual EPS 0 USD

Apellis Pharma

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

U-BX Tech

3 E Network Tech

PMGC

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Bullfrog AI

Jaguar Uranium

Texxon

Classover Holdings - Class B

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

TC BIOPHARM (HOLDINGS) PLC SPON ADS EACH REP 4000 SHS (POST SPLIT)(TCBPY.US)

TC BIOPHARM (HOLDINGS) PLC SPON ADS EACH REP 4000 SHS (POST SPLIT) Stock Performance Chart